Current issue #4, 2016

BIOCAD opposes registration of drug sets

BIOCAD filed a claim against Russia’s Ministry of Health with the arbitration court. It emerged that the company made this move in order to clarify the situation with the registration of drug sets. According to the company’s representatives, such practice may lead to restraint of competition. As an example, BIOCAD set Beyodime consisting of two separate drugs, i.e. pertuzumab and trastuzumab. Pertuzumab is a new medication that is nearly impossible to purchase outside the set; it is not on the VED (Vital and Essential Drug) list. BIOCAD representatives believe that such approach makes it possible for Beyodime manufacturer to basically stay out of the competition in the trastuzumab market.

[PharmVestnik # 4, 09/02/2016, p. 1, cont’d p. 3]

R-Pharm led the development of a road map for a new market segment

At the end of January, the experts discussed a road map of the HealthNet (National Technological Expertise) on the Open Government site. This is a so far unshaped healthcare market that is globally to exceed 100 bn USD by 2035. It is worth noting that the road map workgroup is led by R-Pharm Chairman of the Board Alexey Repik.

[PharmVestnik # 4, 09/02/2016, p. 2]

“One needs to combine calculated risks with sound economy”

The year 2015 was abundant in the legislative changes concerning API manufacture. The relevant ministries were quite careful when developing the local manufacturer support mechanisms, which naturally affected the industry development. Many companies, despite the tough economic situation, saw this fact as an opportunity to build up their production potential and broaden their market presence. Within the framework of the “Editorial Fireplace” rubric, President and co-owner of Active Component Co. Alexander SEMYONOV told about the corporate strategy changes in the new conditions as well as trends prevailing in the Pharma market.

[PharmVestnik # 4, 09/02/2016, p. 4]

Ministry of Health is “twice shy”

MoH’s overvigilance torped...